Faculty Summaries
Gregory P Adams, PhD
Gregory P Adams, PhD
Associate Professor
  • Associate Professor, Department of Microbiology and Immunology, Temple University School of Medicine
  • Co-Leader, Developmental Therapeutics
Gregory.Adams@fccc.edu
Office Phone: 215-728-3890
Fax: 215-728-2741
Office: W364
Antibody-Based Therapy and Detection of Cancer

Our research is focused upon optimizing and exploiting engineered antibody fragments to both detect and treat solid tumors. To accomplish this, we are using phage display and hybridoma technology to develop new antibodies specific for novel tumor antigens. We are using the antibodies that successfully target tumors in vivo in an unconjugated form to directly inhibit tumor growth or employing them as vehicles for the delivery of cytotoxic agents that can kill the tumor cells or positron-emitting radioisotopes to facilitate ImmunoPET tumor detection. We are also employing our engineered antibodies as the basis for nano and micro biosensors for the detection of tumor biomarkers and pathogens in biologic fluids. Additionally, we are examining the impact of antibody affinity and avidity on tumor targeting and penetration, particularly in the setting of background expression of the target antigen on normal tissue.

Description of research projects
Selected Publications
true first
  1. Rudnick SI and Adams, GP. Affinity and Avidity in Antibody-Based Tumor Targeting. Cancer Biotherapy and Radiopharmaceuticals 2009, 2:155-61. PubMed
  2. Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC, von Mehren M, Shchaveleva I, Simmons HH, Marks JD, Adams GP. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer. 2008 Oct;99(9):1415-25. PubMed
  3. Capobianco JA, Shih WY, Yuan Q-A, Adams GP, Shih W-H. Label-free, all-electrical, in situ human epidermal growth receptor 2 detection Review of Scientific Instruments. 2008;79:076101-3. PubMed
  4. Yuan QA, Robinson MK, Simmons HH, Russeva M, Adams GP. Isolation of anti-MISIIR scFv molecules from a phage display library by cell sorter biopanning. Cancer Immunol Immunother. 2008 Mar;57(3):367-78. PubMed
  5. Robinson MK, Shaller C, Garmestani K, Plascjak PS, Hodge KM, Yuan QA, Marks JD, Waldmann TA, Brechbiel MW, Adams GP. Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies. Clin Cancer Res. 2008 Feb 1;14(3):875-82. PubMed
  6. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nature Biotechnol. 2005;23:1147-57. Review. PubMed
  7. Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, Gonzalez Trotter DE, Adams GP. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Research. 2005;65:1471-8. PubMed
  8. Adams GP, Schier R, McCall AM, Simmons H, Horak E, Alpaugh RK, Marks JD, Weiner LM. High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Research. 2001;61:4750-5. PubMed
All publications